Posted by Michael Wonder on 07 Oct 2017
Neurocrine announces FDA approval of 80 mg Ingrezza (valbenazine) capsules for the treatment of adults with tardive dyskinesia
5 October 2017 - First and only tardive dyskinesia therapy taken as one capsule, once per day; new 80 mg capsule expected to be available for patients within two weeks.
Neurocrine Biosciences announced today that the U.S. FDA has approved an 80 mg Ingrezza (valbenazine) capsule strength to be used for the treatment of adults with tardive dyskinesia (TD).
Ingrezza, a novel, selective vesicular monoamine transporter 2 inhibitor, which was approved by the FDA April 11, 2017, is the first FDA-approved product indicated for the treatment of adults with TD.
